Market closed
Aquestive Therapeutics/AQST
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aquestive Therapeutics
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Ticker
AQST
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
135
Website
AQST Metrics
BasicAdvanced
$499M
Market cap
-
P/E ratio
-$0.35
EPS
2.79
Beta
-
Dividend rate
Price and volume
Market cap
$499M
Beta
2.79
52-week high
$6.23
52-week low
$1.36
Average daily volume
1.3M
Financial strength
Current ratio
7.485
Quick ratio
6.899
Long term debt to equity
-99.338
Total debt to equity
-100.688
Interest coverage (TTM)
-1.17%
Management effectiveness
Return on assets (TTM)
-10.87%
Return on equity (TTM)
36.19%
Valuation
Price to revenue (TTM)
6.962
Price to book
-14.06
Price to tangible book (TTM)
-14.06
Price to free cash flow (TTM)
-16.31
Growth
Revenue change (TTM)
25.45%
Earnings per share change (TTM)
-14.67%
3-year revenue growth (CAGR)
11.70%
3-year earnings per share growth (CAGR)
-42.34%
What the Analysts think about AQST
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Aquestive Therapeutics stock.
AQST Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AQST Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AQST News
AllArticlesVideos
Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
GlobeNewsWire·4 weeks ago
Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
GlobeNewsWire·2 months ago
Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aquestive Therapeutics stock?
Aquestive Therapeutics (AQST) has a market cap of $499M as of October 26, 2024.
What is the P/E ratio for Aquestive Therapeutics stock?
The price to earnings (P/E) ratio for Aquestive Therapeutics (AQST) stock is 0 as of October 26, 2024.
Does Aquestive Therapeutics stock pay dividends?
No, Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Aquestive Therapeutics dividend payment date?
Aquestive Therapeutics (AQST) stock does not pay dividends to its shareholders.
What is the beta indicator for Aquestive Therapeutics?
Aquestive Therapeutics (AQST) has a beta rating of 2.79. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.